MacroGenics Inc (NASDAQ:MGNX) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,180,000 shares, an increase of 14.5% from the January 15th total of 3,650,000 shares. Based on an average daily trading volume, of 575,700 shares, the days-to-cover ratio is currently 7.3 days. Currently, 9.5% of the company’s shares are short sold.
Shares of NASDAQ:MGNX opened at $10.16 on Friday. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.11. MacroGenics has a 1 year low of $7.43 and a 1 year high of $22.57. The stock’s fifty day moving average price is $10.62 and its 200-day moving average price is $11.36.
Several institutional investors have recently added to or reduced their stakes in MGNX. Marshall Wace LLP bought a new stake in MacroGenics during the 1st quarter valued at $80,000. Marshall Wace North America L.P. bought a new position in shares of MacroGenics during the first quarter valued at about $59,000. Morgan Stanley raised its stake in shares of MacroGenics by 7.1% during the second quarter. Morgan Stanley now owns 50,602 shares of the biopharmaceutical company’s stock valued at $859,000 after acquiring an additional 3,358 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of MacroGenics during the third quarter valued at about $345,000. Finally, Rhumbline Advisers boosted its holdings in shares of MacroGenics by 6.2% during the third quarter. Rhumbline Advisers now owns 68,282 shares of the biopharmaceutical company’s stock worth $871,000 after purchasing an additional 4,006 shares during the period. 95.44% of the stock is currently owned by institutional investors.
MacroGenics Company Profile
MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.
Further Reading: Risk Tolerance
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.